Pharmaqo Deca 300mg x 10ml

Nandrolone Decanoate

300 Mg/ml

Pharmaqo Deca 300mg x 10ml

Deca 300mg (Nandrolone decanoate), commonly known as nandrolone caprinate, is an alkylated anabolic steroid used as adjuvant treatment for senile and postmenopausal osteoporosis and anemia induced by renal insufficiency. When compared to nandrolone and other esters, the method for producing nandrolone esters was developed in Spain in 1960, and it was found to have a longer duration of action and a substantial anabolic influence.

On October 5, 1962, the FDA authorized nandrolone decanoate.

Anemia induced by renal failure is treated with Deca 300mg (nandrolone decanoate). In Canada, it’s also utilized as a supplement to treat senile and postmenopausal osteoporosis.

Nandrolone decanoate is an alkylated anabolic steroid that is used to treat anemia caused by renal insufficiency, as well as senile and postmenopausal osteoporosis. It has a longer duration of effect due to the fact that it is given every 3-4 weeks, and it has a wide therapeutic window due to the rarity of acute overdoses. The risks of using this medicine should be discussed with patients who have cardiac, renal, or hepatic problems.

PDE7B has the ability to hydrolyze nandrolone decanoate and convert it to nandrolone. Nandrolone interacts with the androgen receptor and enters cells via receptor-mediated endocytosis. The androgen receptor undergoes a conformational change after connecting with the androgen receptor, enters the nucleus, dimerizes, and may then bind to DNA sequences to regulate transcription. Androgens can also regulate transcription through activating ERK, Akt, and MAPK, as well as competitively binding to and inhibiting transcription factors.

Nandrolone is a 19-nortestosterone-derivate AAS that belongs to the class II AASs. AASs are a vast and fast-expanding class of synthetic androgens used both legally and therapeutically.

When compared to testosterone propionate (potency ratios of 3.29–4.92 and 0.31–0.41), Deca 300mg (0nandrolone decanoate) has a substantial anabolic impact but a minor androgenic effect (potency ratios of 3.29–4.92 and 0.31–0.41). The anabolic-to-androgenic ratio of nandrolone esters, for instance, is thought to be the highest of any AAS. The weak androgenic of nandrolone is thought to be due to its inactivation by 5-reductase via transformation into the low-affinity androgen receptor (AR) ligand 5-dihydro nandrolone. The frequency and intensity of negative effects should be reduced as a result of this.

The chemical is well-known not only among adults but also among youngsters due to its anabolic, muscle-building properties. Androgenic receptors, which are up-regulated after exposure to AAS and grow in number with bodybuilding, mediate the anabolic effects of AAS. The major target tissue for AAS’s anabolic effects is skeletal muscle, which is mediated by androgenic receptors, which are up-regulated following exposure to AAS and grow in number with bodybuilding. AAS observe an increase in muscle size, as well as the cross-sectional areas of both type I and type II muscle fibers and myonuclear domains, as a result of dose-dependent hypertrophy.

Dosage

As a therapeutic dose, you should take 0.4 mg/kg/day of ND. However, before beginning any dosage, ask your doctor.

Consequences

Acute Side Effects include:

• Retention of Fluid
• Headache
• abdominal pain
•  gastrointestinal discomfort
• Menstrual irregularities
• Jaundice
• Hypertension
• Diarrhea

Neuropsychiatric and behavioral disorders are examples of chronic side effects.

If any of these symptoms worsen, see your doctor as soon as possible.